Higher-risk MDS and newly diagnosed AML What are the latest developments from EHA 2022
touchCONGRESS for touchONCOLOGY
Listen to Dr Esther Oliva (Italy) review key data presented at the EHA 2022 Hybrid Congress on recent developments in the treatment of higher-risk MDS and newly diagnosed AML; she offers her expert insights on their potential impact on future clinical practice, alongside those from Prof. Michael Heuser (Germany) and Dr Yishai Ofran (Israel).
OVERVIEW
Data review with Dr Oliva (0:00)
Expert interviews with Prof. Heuser, Dr Ofran and Dr Oliva, answering the questions below
INTERVIEW QUESTIONS
Based on data presented at EHA 2022, which emerging treatments are most…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.